94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
STUDY PROTOCOL article
Front. Child Adolesc. Psychiatry
Sec. Autism and Other Neurodevelopmental Disorders
Volume 4 - 2025 | doi: 10.3389/frcha.2025.1547672
Treatment of affective dysregulation in ADHD with Guanfacine: study protocol
Provisionally accepted
Johanna Waltereit 1
Anne Uhlmann 2 Christos Tarassidis 3 Ulrich Preuss 3 Veit Roessner 2
Robert Waltereit 4*- 1 LWL-Klinik Marsberg, Marsberg, Germany
- 2 Department of Child and Adolescent Psychiatry, School of Medicine, Technical University Dresden, Dresden, Lower Saxony, Germany
- 3 Klinikum Lippe, Detmold, North Rhine-Westphalia, Germany
- 4 University Medical Center Göttingen, Göttingen, Germany
The early onset, high prevalence, persistence and comorbidity of developmental disorders make affective dysregulation (AD) in childhood and adolescence one of the conditions with the greatest psychosocial burden and economic impact on society. Despite ongoing research, there remains a substantial need to optimize individualized treatment strategies to improve treatment outcomes and alleviate subjective distress and economic costs. The objective of this study is to investigate psychopathological markers of AD in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) treated with the drug guanfacine as part of routine clinical care. These ADHD patients typically have not responded adequately to methylphenidate or other stimulant treatment.This study will employ a multicenter, single-arm design to evaluate the effects of guanfacine on AD symptoms in n=40 patients of children and adolescents receiving regular ADHD treatment.The findings of this study are expected to address the hypothesis that guanfacine provides beneficial effects on symptoms of AD in addition to its effects on symptoms of ADHD. Public clinical trial registry: Affective Dysregulation (AD) in Children With ADHD Treated by Guanfacin, ClinicalTrials.gov ID NCT04016207.
Keywords: ADHD, Oppositional-defiant disorder, Conduct Disorder, affective dyregulation, emotional dysregulation, Guanfacine
Received: 18 Dec 2024; Accepted: 11 Mar 2025.
Copyright: © 2025 Waltereit, Uhlmann, Tarassidis, Preuss, Roessner and Waltereit. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Robert Waltereit, University Medical Center Göttingen, Göttingen, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.